The Exchange has sought clarification from Indo Us Biotech Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 1.4 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The NSE has asked Indo Us Biotech Limited to explain discrepancies found in the XBRL (digital) filing of its financial results for the quarter ended 30 September 2025, under Regulation 33 of SEBI's listing rules. The company has not yet responded, and its clarification is awaited. This is a routine compliance query about the format or accuracy of electronically filed financial data, not an enforcement action. Investors should wait for the company's reply to understand whether the discrepancy is a technical filing error or something more material. Until the response is filed, the matter remains open with the exchange.
For now, this is a minor compliance flag with limited stock price impact. If the company fails to respond or the issue turns out to be material, it could lead to further regulatory action and negative sentiment.